Current Atherosclerosis Reports

Current Atherosclerosis Reports is a peer-reviewed review journal founded in 1999 and published by Springer Science+Business Media, providing in-depth reviews by international experts on the diagnosis, treatment, management and prevention of atherosclerosis as an online-only title, with a 2025 Journal Impact Factor of 6.6《当代动脉粥样硬化报道》（Current Atherosclerosis Reports）创刊于 1999 年，由施普林格科学商业媒体（Springer Science+Business Media）出版，是只发表综述的同行评审期刊，邀请国际专家就动脉粥样硬化的诊断、治疗、管理与预防撰写深度评述，现为纯在线出版，2025 年影响因子为 6.6。

Scope

• The journal provides in-depth review articles contributed by international experts on the most significant developments in the field of atherosclerosis, presenting clear, insightful and balanced reviews that emphasize recently published papers of major importance该刊发表由国际专家撰写的深度综述，聚焦动脉粥样硬化领域最重要的进展，以清晰、深刻而均衡的评述突出近期发表的重要论文。
• Its reviews elucidate current and emerging approaches to the diagnosis, treatment, management and prevention of atherosclerosis, helping specialists keep pace with an expanding volume of literature其综述阐明动脉粥样硬化诊断、治疗、管理与预防的现有手段与新兴路径，帮助专科医师跟上快速扩张的文献体量。
• Content is limited to review-type articles, with supplementary reviews and commentaries contributed by well-known figures in the field rather than original research reports该刊内容限于综述类文章，并由领域知名人士撰写补充评述与评论，不发表原创研究报告。
• Topical collections run alongside the issues, among them Biomarkers and Omics in Atherosclerosis, Aortic Disease, the Topical Collection on Implementation Science, LP(a) Therapies Now and Tomorrow, Nonstatin Drugs, Clinical Trials and Statins, and Exercise and Atherosclerosis, all open for submissions on an ongoing basis常设专题合集与正刊并行，包括动脉粥样硬化的生物标志物与组学、主动脉疾病、实施科学、脂蛋白（a）疗法的现状与未来、非他汀类药物、临床试验与他汀类药物，以及运动与动脉粥样硬化等，均长期接受投稿。
• Major authorities are appointed as Section Editors who select leading experts from around the world to provide definitive reviews on key topics and on the most important papers published in the past year该刊聘请领域权威人士出任栏目编辑，由他们在全球范围内遴选顶尖专家，就关键选题与过去一年发表的最重要论文撰写权威综述。
• An Editorial Board of internationally diverse members suggests topics of special interest to their own country or region and ensures that the topics covered remain current and include emerging research directions由多国学者组成的编委会为其所在国家或地区特别关注的选题提出建议，并确保所涉主题保持前沿并纳入新兴研究方向。

History

• The journal was established in 1999, with volume 1 opening in September of that year and its first editorial penned by editor-in-chief Antonio M. Gotto Jr, as part of the Current Reports family developed by Current Medicine Group of Philadelphia in recognition that specialists have increasing difficulty keeping up to date with the expanding volume of information in their fields该刊于 1999 年创刊，同年 9 月出版第 1 卷，创刊社论由主编（Antonio M. Gotto Jr）执笔，属费城（Current Medicine Group）旗下当代报道（Current Reports）系列，创办初衷是承认专科医师越来越难以跟上本领域迅猛扩张的文献步伐。^[1]
• Springer Science+Business Media acquired Current Medicine Group in 2005, and the journal has been published by Springer ever since, now bearing the imprint Springer Science+Business Media LLC, part of Springer Nature施普林格科学商业媒体于 2005 年收购（Current Medicine Group），此后该刊一直由施普林格出版，现以施普林格自然（Springer Nature）旗下施普林格科学商业媒体有限责任公司的名义发行。
• The title is now an online-only journal whose print ISSN 1523-3804 has ceased, and articles appear under the electronic ISSN 1534-6242 in continuous publication, numbered sequentially within each annual volume该刊现为纯在线期刊，纸本 ISSN 1523-3804 已停用，论文以电子 ISSN 1534-6242 连续发表，在每一年度卷内顺序编号。
• Antonio M. Gotto Jr has been its editor-in-chief since the early years of the journal, giving the title unusual editorial continuity for a review serial（Antonio M. Gotto Jr）自该刊创刊初期起担任主编，使这本综述类刊物拥有少见的编辑连贯性。
• Its impact factor was 5.113 in 2021 and 5.967 in 2022, stood at 5.2 in 2024 and reached 6.6 in 2025, with a five-year impact factor of 6.7 and a first-quartile rank of 13th among 100 journals in Peripheral Vascular Disease其影响因子 2021 年为 5.113、2022 年为 5.967，2024 年为 5.2，2025 年达 6.6，五年影响因子为 6.7，在外周血管病类别 100 种期刊中列第 13 位、居第一四分位。
• The journal is abstracted and indexed in the Science Citation Index Expanded, MEDLINE, EMBASE, Scopus and Current Contents/Clinical Medicine, reports 764.8 thousand downloads in 2025, and publishes under a hybrid model with an open access option该刊为科学引文索引扩展版（SCIE）、（MEDLINE）、（EMBASE）、（Scopus）与（Current Contents/Clinical Medicine）等收录，2025 年下载量达 76.48 万次，并以混合模式出版、提供开放获取选项。

Editors

• The Editor-in-Chief is Antonio M. Gotto Jr MD, DPhil of Weill Cornell Medicine in New York, a pioneering lipidologist and longtime former president of the American Heart Association whose work spans cholesterol metabolism and cardiovascular prevention主编为纽约威尔康奈尔医学院的（Antonio M. Gotto Jr），医学博士与哲学博士，血脂学先驱、曾任美国心脏协会主席，研究横跨胆固醇代谢与心血管预防。
• Henry J. Pownall PhD of the Houston Methodist Research Institute serves as Associate Editor, covering vascular biology among his duties as a section editor休斯顿卫理公会研究所的（Henry J. Pownall）任副编辑，同时以栏目编辑身份分管血管生物学方向。
• The Editorial Board numbers eleven members from the United States, Czechia, Chile, Israel, Japan, Brazil, Qatar, Turkiye and Australia, among them Christie Ballantyne of Baylor College of Medicine, Peter Libby of Brigham and Women's Hospital, Alan R. Tall of Columbia University, Lale Tokgozoglu of Hacettepe University and Andrew Tonkin of Monash University编委会由 11 位成员组成，来自美国、捷克、智利、以色列、日本、巴西、卡塔尔、土耳其与澳大利亚，其中不乏贝勒医学院的（Christie Ballantyne）、布莱根妇女医院的（Peter Libby）、哥伦比亚大学的（Alan R. Tall）、哈西德佩大学的（Lale Tokgozoglu）与莫纳什大学的（Andrew Tonkin）。
• Section editors are appointed by topic, covering the atherosclerotic plaque, cardiovascular disease and stroke, cardiometabolic disease and treatment, children and young adults, coronary heart disease, exercise and atherosclerosis, genomic science and precision medicine, global cardiovascular disease updates, gut microbiota, implementation science, inflammation and immune mechanisms, obesity drugs, nonstatin drugs, nutrition, pediatric endocrinology and lipid disorders, psychosocial factors, vascular biology and women and ischemic heart disease栏目编辑按主题设置，覆盖动脉粥样硬化斑块、心血管疾病与卒中、心脏代谢性疾病与治疗、儿童与青少年、冠心病、运动与动脉粥样硬化、基因组学与精准医学、全球心血管疾病动态、肠道菌群、实施科学、炎症与免疫机制、肥胖药物、非他汀类药物、营养、儿科内分泌与血脂紊乱、心理社会因素、血管生物学以及女性缺血性心脏病等方向。
• Many section editor pairs combine hospital and university strengths across continents, for example Marcio Hiroshi Miname and Viviane Rocha of the Universidade de Sao Paulo in Brazil for cardiometabolic disease, Liam Brunham and Robert A. Hegele in Canada for genomic science, and Mahmoud Al Rifai and Salim Virani spanning Baylor College of Medicine and Aga Khan University in Pakistan不少栏目编辑组合横跨多洲的医院与大学，如心脏代谢性疾病由巴西圣保罗大学的（Marcio Hiroshi Miname）与（Viviane Rocha）共同负责，基因组学由加拿大的（Liam Brunham）与（Robert A. Hegele）执掌，冠心病则跨越贝勒医学院与巴基斯坦阿迦汗大学的（Mahmoud Al Rifai）和（Salim Virani）。
• Papers are submitted under the Springer continuous publication model with a median of 15 days from submission to first decision, topical collections remain open for submissions, and the editorial office operates with the publisher in New York稿件按施普林格连续出版模式运作，投稿至首次决定的中位数为 15 天，各专题合集持续接受投稿，编辑部与出版方同在纽约办公。